Payment overview · 2025
General Payments
$35.00
1 reported records · 1 companies
Healthcare provider profile · identity verified
Saqib Sheikh, M.D
Allopathic & Osteopathic Physicians|Hospitalist · OKLAHOMA CITY, OK · NPI 1326366899
Verified facts
What the public records show
CMS Open Payments records show Saqib Sheikh, M.D received $35.00 in general payments during 2025 across 1 reported records.
Janssen Biotech, Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $35.00 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $35.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $35.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
85 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 604 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 572 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 79 |
| Furosemide | Furosemide | 400 | 78 |
| Pantoprazole Sodium | Pantoprazole Sodium | 361 | 91 |
| Potassium Chloride | Potassium Chloride | 351 | 76 |
| Gabapentin | Gabapentin | 331 | 74 |
| Metoprolol Tartrate | Metoprolol Tartrate | 227 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 59 |
| Losartan Potassium | Losartan Potassium | 209 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 34 |
| Trazodone Hcl | Trazodone Hcl | 197 | 43 |
| Omeprazole | Omeprazole | 176 | 43 |
| Carvedilol | Carvedilol | 175 | 41 |
| Famotidine | Famotidine | 173 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 31 |
| Buspirone Hcl | Buspirone Hcl | 148 | 32 |
| Sertraline Hcl | Sertraline Hcl | 142 | 38 |
| Mirtazapine | Mirtazapine | 138 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 23 |
| Metformin Hcl | Metformin Hcl | 128 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 29 |
| Donepezil Hcl | Donepezil Hcl | 120 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 120 | 37 |
| Divalproex Sodium | Divalproex Sodium | 119 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 119 | 23 |
| Lisinopril | Lisinopril | 119 | 33 |
| Prednisone | Prednisone | 110 | 45 |
| Myrbetriq | Mirabegron | 109 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 109 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 107 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 38 |
| Sucralfate | Sucralfate | 99 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 19 |
| Torsemide | Torsemide | 93 | 17 |
| Methocarbamol | Methocarbamol | 91 | 22 |
| Montelukast Sodium | Montelukast Sodium | 89 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 21 |
| Xarelto | Rivaroxaban | 85 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 82 | 15 |
| Memantine Hcl | Memantine Hcl | 80 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 79 | 14 |
| Midodrine Hcl | Midodrine Hcl | 79 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 26 |
| Spironolactone | Spironolactone | 78 | 14 |
| Allopurinol | Allopurinol | 77 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 75 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 67 | 26 |
| Linzess | Linaclotide | 61 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 60 | 22 |
| Latanoprost | Latanoprost | 60 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 15 |
| Tradjenta | Linagliptin | 57 | suppressed |
| Trulicity | Dulaglutide | 56 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 54 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 52 | suppressed |
| Levetiracetam | Levetiracetam | 50 | 14 |
| Baclofen | Baclofen | 48 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | suppressed |
| Jardiance | Empagliflozin | 47 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 46 | 27 |
| Finasteride | Finasteride | 45 | 12 |
| Alprazolam | Alprazolam | 44 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 43 | suppressed |
| Hydrocortisone | Hydrocortisone | 43 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 43 | 16 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Loperamide | Loperamide Hcl | 34 | 17 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Simvastatin | Simvastatin | 33 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 31 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Budesonide | Budesonide | 28 | suppressed |
| Anastrozole | Anastrozole | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 18 |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Enulose | Lactulose | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 13 |
| Permethrin | Permethrin | 21 | 18 |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 20 |
| Meloxicam | Meloxicam | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 11 |
| Novolog | Insulin Aspart | 14 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Cephalexin | Cephalexin | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35.00 · 1 records | Janssen Biotech, Inc. | SIMPONI ARIA, TREMFYA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error